Darolutamide’s 2025 U.S. Indication Expansion: What It Means for Two Pyrazole Intermediates

FDA’s 2025 darolutamide indication expansion provides a timely reason to examine two exact Rlavie catalog products disclosed in a public route—and the identity, tautomer and impurity controls that matter when sourcing them.

On June 3, 2025, the U.S. Food and Drug Administration expanded the indication for darolutamide (Nubeqa) to include adults with metastatic castration-sensitive prostate cancer (mCSPC). This was an indication expansion, not darolutamide’s first approval. The FDA had previously approved darolutamide in combination with docetaxel for mCSPC; the 2025 action added a regimen of darolutamide with androgen-deprivation therapy without docetaxel.

For process-development and sourcing teams, that regulatory event provides useful context for examining two pyrazole compounds found in public darolutamide synthesis disclosures: 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile, CAS 1297537-37-1, and 5-acetyl-1H-pyrazole-3-carboxylic acid, CAS 1297537-45-1.

What ARANOTE showed—and what it did not

ARANOTE was a randomized, double-blind, placebo-controlled Phase III trial in 669 patients with mCSPC. Participants received darolutamide or placebo, with androgen-deprivation therapy in both groups. The primary endpoint was radiographic progression-free survival assessed by blinded independent central review.

The FDA reported that median radiographic progression-free survival was not reached with darolutamide and was 25 months with placebo. The hazard ratio was 0.54 (95% CI, 0.41–0.71; p<0.0001), corresponding to a 46% lower risk of radiographic progression or death during the trial observation period.

The boundary is equally important: at the final analysis, overall survival was not statistically significantly improved (HR 0.78; 95% CI, 0.58–1.05). The trial compared darolutamide plus androgen-deprivation therapy with placebo plus androgen-deprivation therapy, not with another androgen-receptor pathway inhibitor. FDA also noted that adverse reactions were consistent with prior experience with darolutamide as a single agent.

The regulatory expansion broadens an evidence-based treatment option; it does not validate a particular manufacturing route, intermediate source or forecast of market demand.

How two Rlavie-listed compounds enter a disclosed synthesis

Public process patent WO2016/162604 describes one route rather than the only possible—or necessarily current commercial—route. It prepares 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile through Suzuki coupling of a protected pyrazole boronate with 4-bromo-2-chlorobenzonitrile, followed by deprotection and crystallization. The patent calls this compound a key intermediate.

The pyrazolyl benzonitrile is then used in a Mitsunobu-type N-functionalization with an (S)-Boc-protected amino alcohol and subsequently deprotected to give a chiral aminopropyl intermediate.

A second branch uses 3-acetyl-1H-pyrazole-5-carboxylic acid—another tautomeric name used for Rlavie-listed 5-acetyl-1H-pyrazole-3-carboxylic acid, CAS 1297537-45-1. The public route couples this acid with the chiral amine to form a ketone-bearing carboxamide intermediate. Reduction of that ketone then furnishes the alcohol-containing darolutamide framework.

The sequence provides an exact public-route relationship for both Rlavie products. It does not establish that Rlavie material was used by the patent owner or in any clinical or commercial batch.

Why pyrazole naming requires care

Both listed materials contain an N–H pyrazole. Proton transfer between the two ring nitrogens can make the same substance appear under 3- and 5-position names. The process patent explicitly treats “2-chloro-4-(1H-pyrazol-3-yl)benzonitrile” and its 5-yl name as tautomers.

Likewise, CAS 1297537-45-1 is encountered as either 5-acetyl-1H-pyrazole-3-carboxylic acid or 3-acetyl-1H-pyrazole-5-carboxylic acid. These paired names should not automatically be interpreted as two different products.

Tautomerism and regioisomerism are not interchangeable, however. Once an unsymmetrical pyrazole is N-substituted, alternative N-functionalization pathways can lock different connectivities and create analytically distinct regioisomers. Because such regioisomers can share the same formula and exact mass, mass confirmation alone does not prove connectivity. A fit-for-purpose package may therefore combine structure-confirming NMR with a chromatographic method capable of resolving relevant related substances.

Process-control and purchasing significance

For CAS 1297537-37-1, route-aware evaluation may include orthogonal identity confirmation, chromatographic control of positional or N-functionalization-related impurities in downstream use, water, residual solvents and elemental impurities such as residual palladium when a Suzuki route is used. The public process patent specifically discusses reducing palladium-catalyst loading; any residual-metal limit would still need to be defined for the buyer’s own route and intended use.

For CAS 1297537-45-1, useful controls may include the residual ester precursor, related pyrazole isomers, assay, water and residual solvents. A 2023 peer-reviewed process paper described a diazo-free preparation of this compound and emphasized regioselectivity, safety and scalability, illustrating why a single percentage-purity result may not answer every route-specific question.

A purchase specification should align the CAS number, drawn structure, tautomeric synonyms, analytical method and intended use. Requirements for route scouting may differ materially from those for later-stage regulated development, so documentation and change-control expectations should be agreed before ordering.

Connecting the public route to Rlavie’s catalog

Rlavie lists both CAS 1297537-37-1 and CAS 1297537-45-1. Teams evaluating these materials for route scouting, process development or custom synthesis can contact Rlavie to discuss current specifications, analytical documentation, quantities and project requirements.

This review connects public regulatory and synthesis information only. It does not imply that Rlavie supplied Bayer, Orion, the ARANOTE trial or any clinical or commercial darolutamide program.

Sources

This article is an industry and process-chemistry overview. It does not constitute medical, regulatory or investment advice.